GAA and type 2 diabetes mellitus: The lipid-lowering effect of anagliptin was first demonstrated in a phase III trial comparing anagliptin to placebo as a single agent or with concurrent anti-diabetic treatment, such as alpha-glucosidase inhibitors, biguanide, sulfonylurea, or thiazolidine in type 2 diabetic patients for 12 weeks [9].